Vera Therapeutics, Inc. (NASDAQ:VERA) is Avoro Capital Advisors LLC's 9th Largest Position

Avoro Capital Advisors LLC lifted its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 30.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,610,000 shares of the company's stock after purchasing an additional 1,300,410 shares during the quarter. Vera Therapeutics accounts for approximately 3.4% of Avoro Capital Advisors LLC's holdings, making the stock its 9th biggest position. Avoro Capital Advisors LLC owned approximately 8.86% of Vera Therapeutics worth $237,247,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Federated Hermes Inc. boosted its position in shares of Vera Therapeutics by 162.2% during the fourth quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company's stock valued at $45,926,000 after buying an additional 671,881 shares during the last quarter. Vanguard Group Inc. lifted its position in Vera Therapeutics by 14.3% during the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock valued at $124,737,000 after purchasing an additional 369,387 shares during the period. Jennison Associates LLC boosted its holdings in Vera Therapeutics by 82.0% in the fourth quarter. Jennison Associates LLC now owns 813,861 shares of the company's stock worth $34,418,000 after purchasing an additional 366,763 shares during the last quarter. Pictet Asset Management Holding SA grew its position in Vera Therapeutics by 47.1% in the 4th quarter. Pictet Asset Management Holding SA now owns 841,313 shares of the company's stock worth $35,579,000 after purchasing an additional 269,315 shares during the period. Finally, FMR LLC raised its stake in Vera Therapeutics by 9.6% during the 4th quarter. FMR LLC now owns 3,053,126 shares of the company's stock valued at $129,117,000 after buying an additional 267,842 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Price Performance

Shares of NASDAQ:VERA traded down $0.25 during mid-day trading on Friday, reaching $23.22. The stock had a trading volume of 906,424 shares, compared to its average volume of 748,851. The company has a market cap of $1.48 billion, a P/E ratio of -8.90 and a beta of 1.28. The business's 50 day moving average price is $25.27 and its 200 day moving average price is $35.91. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11. Research analysts expect that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VERA has been the subject of a number of recent research reports. Wolfe Research began coverage on Vera Therapeutics in a research note on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price target for the company. Guggenheim raised their target price on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They set a "buy" rating and a $58.00 price objective for the company. Finally, JPMorgan Chase & Co. dropped their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $64.67.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.